

# PRESS RELEASE

# ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2021-03-03

## ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2021

**Strong sales growth during February; Zinzino group revenue increased with a total of 33%, compared with the previous year.**

The revenue in February for Zinzino's sales markets increased by 30% to SEK 94.4 (72.5) million due to strong growth in several regions. Faun Pharma's external sales increased by 81% and amounted to SEK 6.7 (3.7) million. Overall, the Group increased revenues by 33% to SEK 101.1 (76.2) million compared with the previous year.

Accumulated revenue for January – February 2021 increased by 29% SEK 208.1 (161.9) million.

Revenues were distributed as follows:

| Regions,MSEK         | 21-feb       | 20-feb      | Change     | YTD 2021     | YTD 2020     | Change     |
|----------------------|--------------|-------------|------------|--------------|--------------|------------|
| The Nordics          | 27.5         | 29.5        | -7%        | 57.5         | 62.3         | -8%        |
| Central Europe       | 16.7         | 10.4        | 61%        | 34.9         | 23.1         | 51%        |
| East Europe          | 22.3         | 19.4        | 15%        | 49.6         | 39.2         | 27%        |
| South & West Europe  | 11.5         | 4.2         | 174%       | 21.5         | 8.0          | 169%       |
| The Baltics          | 5.5          | 5.2         | 6%         | 11.3         | 10.8         | 5%         |
| North America        | 3.8          | 2.7         | 41%        | 7.4          | 5.3          | 40%        |
| Asia-Pacific         | 7.1          | 1.1         | 545%       | 13.8         | 2.6          | 431%       |
| <b>Zinzino</b>       | <b>94.4</b>  | <b>72.5</b> | <b>30%</b> | <b>196.0</b> | <b>151.3</b> | <b>30%</b> |
| Faun Pharma          | 6.7          | 3.7         | 81%        | 12.1         | 10.6         | 14%        |
| <b>Zinzino Group</b> | <b>101.1</b> | <b>76.2</b> | <b>33%</b> | <b>208.1</b> | <b>161.9</b> | <b>29%</b> |

### Countries in regions:

- The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
- Central Europe: Austria, Germany, Switzerland
- East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
- South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom
- The Baltics: Estonia, Latvia, Lithuania
- North America: Canada, USA
- Asia-Pacific: Australia, Hong Kong, Malaysia, Singapore, Taiwan, Thailand

### For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, [zinzino.com](mailto:zinzino.com)

### Pictures for publication free of charge:

Marcus Tollbom +46 (0) 70 190 03 12, [marcus.tollbom@zinzino.com](mailto:marcus.tollbom@zinzino.com)

**Certified Adviser:** Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 15:30 the 3rd of March 2021.

Zinzino AB (publ.) is a global direct sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong and Malaysia. Zinzino is a public limited company and its shares are listed on Nasdaq First North Premier Growth Market.